English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The consumption of trastuzumab in oncological mixtures Unit (UMO) of the Hospital Nacional Edgardo Rebagliati Martins was studied during 2009 through retrospective descriptive analysis of the worksheets from the UMO and using of Hospital Management System (SGH) and analysis of written and dispensed prescriptions. The results show that the cost accounting of chemotherapy schemes was S/.72798,21 for each patient, still the most widely consumed trastuzumab more ixabepilone mixture with an average cost for six cycles S/. 68684, 52. The UMO attended 542 prescriptions and 521 preparations with trastuzumab, which generated an expense of S/. 3798426 and refunds amounted to S/. 704442, this generated a savings of 18,55%.

Consumo de trastuzumab en la unidad de mezclas oncológicas del Hospital Nacional Edgardo Rebagliati Martins, enero-diciembre 2009